BrainsWay Stock Gains On FDA Expanded Use Approval For Its Stimulation Device

by Vandana Singh, Benzinga Editor

August 18, 2021 8:03 AM | 1 min read |

The FDA has cleared BrainsWay Ltd's BWAY Deep Transcranial Magnetic Stimulation (Deep TMS) System to reduce comorbid anxiety symptoms in adult patients with depression, also known as anxious depression.
BrainsWay submitted data from 573 patients in support of its application to the FDA.
The data demonstrated a treatment effect that was consistent, robust, and clinically meaningful for decreasing anxiety symptoms in adult patients suffering from a major depressive disorder.
An analysis of the BrainsWay data found favorable outcomes with Deep TMS compared to sham or medication as a standard of care.
Related content: Benzinga's Full FDA Calendar.
Price Action: BWAY Stock is up 18.4% at $9.00 during the premarket session on the last check Wednesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.